Fluoxymesterone

Drug Profile

Fluoxymesterone

Alternative Names: Androfluorene; Androfluorone; Android-F; Androsterolo; Fluotestin; Fluoxymesterone CIII; Halotestin; Ora-Testryl; Oralsterone; Oratestin; Stenox; Testoral; Ultandren

Latest Information Update: 26 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Atlantil Labs; Bouty; Brown Pharmaceuticals; Novartis; Pfizer; Rosemont Pharmaceutical Corporation; Sanofi; Sanofy-Midy; Squibb
  • Class Androstenediols; Fluorinated steroids; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Delayed puberty; Hypogonadism

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 24 Nov 2000 A study in patients with breast cancer has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top